Pathologic response after modern radiotherapy for non-small cell lung cancer

被引：8

作者：

Roy, Simon F. ^{[1
]}

Louie, Alexander, V ^{[2
]}

Liberman, Moishe ^{[3
]}

Wong, Philip ^{[4
]}

Bahig, Houda ^{[4
]}

机构：

[1] Univ Montreal, Dept Pathol, Montreal, PQ, Canada

[2] Sunnybrook Hlth Sci Ctr, Dept Radiat Oncol, Toronto, ON, Canada

[3] Ctr Hosp Univ Montreal, Div Thorac Surg, Dept Surg, Montreal, PQ, Canada

[4] Ctr Hosp Univ Montreal, Dept Radiat Oncol, 1051 Sanguinet St, Montreal, PQ, Canada

来源：

TRANSLATIONAL LUNG CANCER RESEARCH | 2019年 / 8卷

关键词：

Stereotactic ablative radiotherapy (SABR); non-small cell lung cancer (NSCLC); pathologic complete response (pCR); STEREOTACTIC ABLATIVE RADIOTHERAPY; BODY RADIATION-THERAPY; 7-YEAR FOLLOW-UP; PHASE-II TRIAL; SURGICAL RESECTION; SUPERIOR SULCUS; NEOADJUVANT CHEMORADIATION; INDUCTION CHEMORADIATION; DISEASE RECURRENCE; LOCAL RECURRENCE;

D O I：

10.21037/tlcr.2019.09.05

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In non-small cell lung cancer (NSCLC), pathologic complete response (pCR) following radiotherapy treatment has been shown to be an independent prognostic factor for long-term survival, progression-free survival and locoregional control. PCR is considered a surrogate to therapeutic efficacy, years before survival data are available, and therefore can be used to guide treatment plans and additional therapeutic interventions post-surgical resection. Given the extensive fibrotic changes induced by radiotherapy in the lung, radiological assessment of response can potentially misrepresent pathologic response. The optimal timing for assessment of pathologic response after conventionally fractionated radiotherapy and stereotactic ablative radiotherapy (SABR) remain poorly understood. In this review, we summarize recent literature on pathologic response after radiotherapy for early stage and locally advanced NSCLC, we discuss current controversies around radiological considerations, and we present upcoming trials that will provide insight into current knowledge gaps.

引用

页码：S124 / S134

页数：11

共 78 条

[1] Pre-treatment 18F-FDG PET-based radiomics predict survival in resected non-small cell lung cancer [J].

Ahn, H. K. ;

Lee, H. ;

Kim, S. G. ;

Hyun, S. H. .

CLINICAL RADIOLOGY, 2019, 74 (06) :467-473

[2] Vulvar Acanthosis With Altered Differentiation (VAAD): Report of a Case With Progression to Poorly Differentiated Carcinoma Over a 5-Yr Period [J].

Al-Bannai, Raeda ;

Miller, Dianne ;

Sadownik, Leslie ;

Gilks, C. Blake .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2015, 34 (04) :385-389

[3] Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial [J].

Albain, Kathy S. ;

Swann, R. Suzanne ;

Rusch, Valerie W. ;

Turrisi, Andrew T., III ;

Shepherd, Frances A. ;

Smith, Colum ;

Chen, Yuhchyau ;

Livingston, Robert B. ;

Feins, Richard H. ;

Gandara, David R. ;

Fry, Willard A. ;

Darling, Gail ;

Johnson, David H. ;

Green, Mark R. ;

Miller, Robert C. ;

Ley, Joanne ;

Sause, Willliam T. ;

Cox, James D. .

LANCET, 2009, 374 (9687) :379-386

[4] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[5] Clinical Prediction of Pathologic Complete Response in Superior Sulcus Non-Small Cell Lung Cancer [J].

Antonoff, Mara B. ;

Hofstetter, Wayne L. ;

Correa, Arlene M. ;

Bell, Jennifer M. ;

Sepesi, Boris ;

Rice, David C. ;

Vaporciyan, Ara A. ;

Walsh, Garrett L. ;

Mehran, Reza J. ;

Swisher, Stephen G. ;

Meyers, Bryan F. .

ANNALS OF THORACIC SURGERY, 2016, 101 (01) :211-217

[6] SUBLETHAL DAMAGE, POTENTIALLY LETHAL DAMAGE, AND CHROMOSOMAL-ABERRATIONS IN MAMMALIAN-CELLS EXPOSED TO IONIZING-RADIATIONS [J].

BEDFORD, JS .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 21 (06) :1457-1469

[7] Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer [J].

Beer, Lucian ;

Hochmair, Maximilian ;

Haug, Alexander R. ;

Schwabel, Bernhard ;

Kifjak, Daria ;

Wadsak, Wolfgang ;

Fuereder, Thorsten ;

Fabikan, Hannah ;

Fazekas, Andreas ;

Schwab, Sophia ;

Mayerhoefer, Marius E. ;

Herold, Christian ;

Prosch, Helmut .

CLINICAL NUCLEAR MEDICINE, 2019, 44 (07) :535-543

[8] Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer:: 5-year follow-up of a phase II study [J].

Betticher, DC ;

Schmitz, SFH ;

Tötsch, M ;

Hansen, E ;

Joss, C ;

von Briel, C ;

Schmid, R ;

Pless, M ;

Habicht, J ;

Roth, AD ;

Spiliopoulos, A ;

Stahel, R ;

Weder, W ;

Stupp, R ;

Egli, F ;

Furrer, M ;

Honegger, H ;

Wernli, M ;

Cerny, T ;

Ris, HB .

BRITISH JOURNAL OF CANCER, 2006, 94 (08) :1099-1106

[9] Combining immunotherapy and radiotherapy in lung cancer [J].

Bhalla, Neeraj ;

Brooker, Rachel ;

Brada, Michael .

JOURNAL OF THORACIC DISEASE, 2018, 10 :S1447-S1460

[10]

BLOEDORN FG, 1964, AMER J ROENTGENOL RA, V92, P77

← 1 2 3 4 5 6 7 8 →